
    
      This Phase 2, multicenter, open-label study will evaluate the safety, tolerability, efficacy,
      and durability of efficacy of ATI-502 Topical Solution, 0.46% for the treatment of alopecia
      areata (AA), alopecia universalis (AU) and alopecia totalis (AT) in adult subjects who
      completed 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension.

      Subjects who complete 24 weeks of active treatment with ATI-501 Oral Suspension or Placebo
      Suspension in study ATI-501-AUAT-201 will be assessed for eligibility to enter the study. At
      Visit 9 in study ATI-501-AUAT-201, subjects who did not experience any adverse events (AEs),
      serious adverse events (SAEs), or tolerability issues that met study discontinuation criteria
      in study ATI-501-AUAT-201 and who in the opinion of the investigator are capable of
      re-growing or maintaining scalp hair and meet the entry criteria are eligible to enroll in
      this open-label study.

      Enrolled subjects will apply ATI-502 Topical Solution, 0.46% BID to the entire scalp and if
      applicable, the eyebrow(s) and return for safety and efficacy assessments as detailed in the
      Schedule of Assessments (Table 3). Assessment of response to treatment will be performed at
      Week 4, Week 8, Week 16, Week 24, and post-treatment Week 28. Safety and tolerability will be
      evaluated at each study visit by assessment of adverse events, clinical laboratory tests, and
      vital signs, and at Week 24, and physical examination findings
    
  